BMRN

BIOMARIN PHARMACEUTI

Health Care·Biotechnology·$10.3B

Reported·Q3-2015

BioMarin Pharmaceuticals Beats on EPS, Stock Up 0.1%

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	+9.64%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

More Earnings This Week

ADCReported

AGREE RLTY CORP REIT

Oct 26, 2015

CDNSReported

CADENCE DESIGN SYS I

Oct 26, 2015

MPWRReported

MONOLITHIC PWR SYS I

Oct 26, 2015

MSTRReported

STRATEGY INC A

Oct 26, 2015

Management Commentary

Tone: Cautiously Optimistic

Management conveyed a cautiously optimistic outlook regarding their product pipeline. They emphasized the importance of upcoming launches and operational efficiency.

Management highlighted ongoing progress in their pipeline.

They expressed confidence in future product launches.

There was a focus on maintaining operational efficiency.

What It Means

BioMarin's earnings report showed a smaller-than-expected loss per share, which contributed to a slight increase in stock price. The positive EPS surprise indicates some level of operational efficiency, even without revenue figures. Investors may be encouraged by the management's focus on future product launches, although the lack of guidance leaves some uncertainty.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime